TDM-guided Crushed Sofosbuvir-velpatasvir Treatment: A case study

Sébastien Lalanne (1, 2, 3) , Caroline Jezequel (1) , Camille Tron (1, 2, 3) , Marie-Clémence Verdier (3, 2) , Marion Mercerolle (1) , Charlotte Pronier (1) , Dominique Guyader (2, 1) , Florian Lemaitre (1, 2, 3)

1 CHU Pontchaillou [Rennes]
2 CIC - Centre d'Investigation Clinique [Rennes]
3 UR Médecine - Université de Rennes - Faculté de Médecine

In this study, the authors report the case of a patient diagnosed with hepatitis C virus who was treated with sofosbuvir-velpatasvir (400/100 mg). As the patient was unable to swallow whole tablets, therapeutic drug monitoring was performed to evaluate the effect of crushing sofosbuvir-velpatasvir tablets on drug absorption and global exposure.

Domains: Life Sciences [q-bio]; Pharmaceutical sciences; Pharmacology; Life Sciences [q-bio]; Human health and pathology; Infectious diseases

Sébastien Lalanne, Caroline Jezequel, Camille Tron, Marie-Clémence Verdier, Marion Mercerolle, et al.. TDM-guided Crushed Sofosbuvir-velpatasvir Treatment: A case study. Therapeutic Drug Monitoring, 2020, 42 (2), pp.163-164. ⟨10.1097/FTD.0000000000000718⟩. ⟨hal-02440785⟩